Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
Condition(s):Hematological MalignanciesLast Updated:December 24, 2007Unknown status
Hide Studies Not Open or Pending
Condition(s):Hematological MalignanciesLast Updated:December 24, 2007Unknown status
Condition(s):HIV-1-infectionLast Updated:May 23, 2017Unknown status
Condition(s):Infections; ChildLast Updated:April 3, 2009Completed
Condition(s):SARS-CoV-2 Infection Covid19Last Updated:January 26, 2022Withdrawn
Condition(s):COVID-19Last Updated:December 14, 2022Completed
Condition(s):Hematologic Diseases; Stem Cell Transplant Complications; Cytomegalovirus Viremia; Herpesvirus InfectionLast Updated:November 25, 2022Completed
Condition(s):Hematological MalignancyLast Updated:March 3, 2015Completed
Condition(s):Infection; Adverse EffectsLast Updated:December 17, 2008Completed
Condition(s):Vaccine Overdose of Undetermined IntentLast Updated:October 31, 2012Unknown status
Condition(s):Clostridium Difficile Infection; VRE Infection; Nosocomial Infection; MRGN BacteriaLast Updated:July 31, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.